Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China
Abstract Background The objective of this study was to investigate the clinical and genetic characteristics and clinical relevance of HER2 exon 20 oncogenic variants in non-small cell lung cancer (NSCLC) patients. Methods This prospective study analyzed 51 NSCLC patients with HER2 mutations, identif...
Saved in:
| Main Authors: | Yating Hou, Xingyang Xue, Zhuoyun Zhang, Dahai Mai, Wei Luo, Mingyu Zhou, Zichuan Liu, Yisheng Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14125-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
by: Lan Shen, et al.
Published: (2025-08-01) -
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context
by: Yang Xia, et al.
Published: (2025-03-01) -
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01) -
Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature
by: Guangjian Yang, et al.
Published: (2025-01-01) -
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)